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Endothelial Injury at a Transiently Occluded
Coronary Artery Increases Myocardial
Leukocyte Content and Necrosis. Effect of
Aspirin
Group LVDP RPP LVEDP CF
control (n = 8) 36 ± 5 32 ± 6 97 ± 4 50 ± 4
Losartan (n = 8) 55 ± 3· 58 ± 5· 27 ± 7· 77 ± 3·
*p < 0.05 vs controls
Evidence for a Role of Angiotensin II on
Neutrophil-Mediated Injury In Postischemic
Hearts
Emad A. Mikhail. Jay L. Zweier. Giuseppe Ambrosio. The Johns Hopkins Medical
Institutions, Baltimore, MD
Losartan treatment resulted in enhanced recovery of contractile function,
and it also significantly decreased cardiac PMN retention (55 ± 7% in con-
trol hearts vs 11 ± 4% in Losartan-treated hearts; p > 0.05). These results
demonstrate that blocking A-II receptors can effectively reduce cardiac injury
in a model characterized by marked neutrophil-mediated damage, thus indi-
cating that A-II may play an important role in myoca rdial ischemia/reperfusion
injury.
Recent evidence indicates that Angiotensin II (A-II) can be formed in ischemic
hearts. Locally released A-II might exert deleterious effects in the setting of
acute myocardial ischemiafreperfusion, including activation and adhesion of
neutrophils (PMNs), with release of proinflammatory substances which may
aggravate injury. To directly study the role of A-II in myocardial postischemic
injury. we used the A-II receptor antagonist Losartan in an isolated rat heart
model perfused with PMNs and plasma. Control hearts were subjected to
20 min of total global ischemia. PMNs (3 x 107 and 5% rat plasma) were
infused over the initial 5 min of reflow, followed by 40 min of reperfusion
with standard buffer. Treated hearts received Losartan (1 JLM) for 2 min prior
to ischemia, and for the initial 15 min of reflow. Left ventricular developed
pressure (LVDP), rate-pressure product (RPP). coronary flow (CF) (% of base-
line). and left ventricular end diastolic pressure (LVEDP; mmHg) at the end
of reperfusion are shown.
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Coronary ligature with minimal intimal injury reproduces only in part acute
coronary syndrome. in which reperfusion occurs through an extensively
damaged artery. To analyze the influence of coronary endothelial injury (El)
on PMN leukocyte accumulation and infarct size. 48 pigs were allocated
to catheterization and endothelial denudation of the LAD or to no interven-
tion immediately before a 48 min coronary occlusion and 6 h of reperfusion.
Ninety min before they had received aspirin (ASA, 250 mg e.v.), or placebo
(2 x 2 factorial design). Twelve animals presented reocclusion and were ex-
cluded for subsequent analysis. 2 of them receiving ASA and 10 not (p <
0.05). In the remaining pigs, blood flow (mll[min.g]) in the area at risk was
similar in those with than in those without EI. 30 min (2.2 ± 0.3 vs 2.3 ± 0.4)
and 5 h (1.4 ± 0.2 vs 1.4 ± 0.2) after reflow. and was not modified by ASA.
Infarct size (% of the area at risk, TIC reaction) was greater in pigs with EI. A
significant interaction (p = 0.03) between El and ASA was detected, El being
associated with larger infarcts in animals receiving placebo. but not in those
receiving ASA:
Myocardial content of PMNs (quantitative histology) in the area at risk was
higher in animals with than in those without El (mean scores 4.9 ± 0.6 vs 3.0
± 0.6. p = 0.04), and was not modified by ASA. In 12 additional experiments
with 30 min coronary occlusion (no infarct), the content of Tc99 labeled PMNs
in the area at risk was significantly increased in pigs with El (144 ± 23% of
control myocardium). but not in those without (p = 003). Thus, El at the site
of a transient coronary occlusion increases myocardial PMN content and
necrosis. ASA reduces reocclusion rate and limits the deleterious effect of
EI on infarct size in animals without reocclusion. This effect could be due to
impared PMN-platelet cooperation. or to a direct effect of ASA on function
of adhered PMNs.
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Reduced Infarct Size and Improved Myocardial
Blood Flow Following Ischemia and Reperfusion
by a Non-peptide Endothelin Receptor
Antagonist
Failure of Endothelin-1 Receptor Blockade
During Ischemia and Reperfusion to Prevent
Ischemic Damage in Isolated Rabbit Hearts
Jean F. Goudemant, Isabelle Mottet, Hubert Pouleur. Roger Demeure.
Jacques Melin, Jean L. Vanoverschelde. University of Louvain. Brussels. Belgium
The aim of the present study was to investigate the effect of the non-peptide
endothelin receptor antagonist Ro 47-0203 (Bosentan) on hemodynamic re-
sponses and infarct size following myocardial ischemia and reperfusion (Ml-
R) in anesthetized open chest pigs. Ischemia was induced by ligation of the
left anterior descending coronary artery (LAD) for 45 min followed by 4 h of
reperfusion. Ro 47-0203 was administered as a systemic iv bolus injection
(5 mg/kg) 15 min before induction of ischemia (n = 6) or by coronary venous
retroinfusion (4 ~glkg/min) for 25 min starting at 30 min of ischemia (n = 4).
Control groups received saline iv (n = 6) or by coronary venous retroinfusion
(n = 5).
Systemic iv administration of Ro 47-0203 reduced mean arterial blood
pressure from 96 ± 5 to 88 ± 5 mmHg (P < 0.05) but did not affect heart rate
or coronary vascular resistance. During Ml-R arterial blood pressure, heart
rate and the rate pressure product were not significantly different between
the Ro 47-0203 iv group and controls. In the control group, LAD blood flow
was reduced from 11.2 ± 2.3 mllmin before ischemia to 5.4 ± 1.1 mllmin (P
< 005) at the end of reperfusion. Blood flow at the end of reperfusion in the
group given Ro 47-0203 iv (1 0.8 ± 1.6 mllmin) was higher than in the control
group (P < 0.05) and similar to the pre-ischemic value (11.4 ± 1.3 ml/minl.
The infarct size was significantly smaller in the Ro 47-0203 iv group than in
the control group (32 ± 5 vs 77 ± 3% of the myocardial area at risk; P <
0.01). Local administration of Ro 47-0203 by coronary venous retroinfusion
reduced the infarct size to the same extent as systemic iv administration
without affecting systemic blood pressure. The study shows that the non-
peptide endothelin receptor antagonist Ro 47-0203 reduces the infarct size
and improves blood flow in the reperfused myocardium. The effect seems
to be mediated via a local action. These results indicate that endogenous
endothelin is of pathophysiological significance for the development of MI-R
injury.
To evaluate the contribution of endogenous Endothelin-l (ET-1) production
to ischemiafreperfusion injury, the effects of REA001, a potent ET-1 recep-
tor antagonist, were delineated in paced isolated rabbit hearts subjected to
60 min low-flow ischemia (6% of baseline) followed by reperfusion. Under-
lying energetic changes were evaluated by use of 31 P NMR to measure ATP.
CrP. Pi, and pH. Results of 9 isovolumic controls were compared with those
of 17 hearts treated 10-5 M REA001, added to the perfusate 6 minutes be-
fore ischemia and continued until the end of ischemia (n = 91 or until that of
reperfusion (n = 8). REA001 did not significantly influence the time of onset
of ischemic contracture (32 ± 4 vs 21 ± 4 min. p = 0.08) or its amplitude (30
± 5 vs 35 ± 6 mmHg. p = ns). Similarly, after 60 min of ischemia. REA001
did not prevent the rise in Pi (to 58 ± 6 vs 72 ± 7 ~mollg dw. p = ns), and
the fall in intracellular pH (to 6.3 ± 0.1 vs 6.2 ± 0.1. p = ns), and did not
decrease the severity of CrP (11 ± 1 vS 8 ± 2 ~mol/g dw, p = ns) and ATP
(9 ± 1 vs 8 ± 2 ~mollg dw, p = nsl depletion. With reperfusion, recovery
of developed pressure was similar among hearts from the control group (55
± 29%) and those treated with REA001 either during ischemia (74 ± 16%)
or during both ischemia and reperfusion (64 ± 19%. p = ns ANOVA). Sim-
ilarly, REA001 did not modify metabolic recovery, as the concentrations of
CrP. ATP and Pi remained similar in the 3 groups of hearts throughout reper-
fusion. Our data indicate that ET-1 receptor blockade during ischemia and
reperfusion does not influence ischemia-reperfusion injury in isolated rabbit
hearts. These results suggest that endogenous production of ET-l is not an
important determinant of ischemicfreperfusion injury.
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